Literature DB >> 22391549

Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain.

Martina Bielaszewska1, Evgeny A Idelevich, Wenlan Zhang, Andreas Bauwens, Frieder Schaumburg, Alexander Mellmann, Georg Peters, Helge Karch.   

Abstract

The role of antibiotics in treatment of enterohemorrhagic Escherichia coli (EHEC) infections is controversial because of concerns about triggering hemolytic-uremic syndrome (HUS) by increasing Shiga toxin (Stx) production. During the recent large EHEC O104:H4 outbreak, antibiotic therapy was indicated for some patients. We tested a diverse panel of antibiotics to which the outbreak strain is susceptible to interrogate the effects of subinhibitory antibiotic concentrations on induction of stx(2)-harboring bacteriophages, stx(2) transcription, and Stx2 production in this emerging pathogen. Ciprofloxacin significantly increased stx(2)-harboring phage induction and Stx2 production in outbreak isolates (P values of <0.001 to <0.05), while fosfomycin, gentamicin, and kanamycin insignificantly influenced them (P > 0.1) and chloramphenicol, meropenem, azithromycin, rifaximin, and tigecycline significantly decreased them (P ≤ 0.05). Ciprofloxacin and chloramphenicol significantly upregulated and downregulated stx(2) transcription, respectively (P < 0.01); the other antibiotics had insignificant effects (P > 0.1). Meropenem, azithromycin, and rifaximin, which were used for necessary therapeutic or prophylactic interventions during the EHEC O104:H4 outbreak, as well as tigecycline, neither induced stx(2)-harboring phages nor increased stx(2) transcription or Stx2 production in the outbreak strain. These antibiotics might represent therapeutic options for patients with EHEC O104:H4 infection if antibiotic treatment is inevitable. We await further analysis of the epidemic to determine if usage of these agents was associated with an altered risk of developing HUS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391549      PMCID: PMC3370775          DOI: 10.1128/AAC.06315-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis.

Authors:  F Proulx; J P Turgeon; G Delage; L Lafleur; L Chicoine
Journal:  J Pediatr       Date:  1992-08       Impact factor: 4.406

2.  Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors.

Authors:  Malene Gantzhorn Pedersen; Claus Hansen; Erik Riise; Søren Persson; Katharina E P Olsen
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

3.  Antimicrobials effective for inhibition of enterohaemorrhagic Escherichia coli strains O26, O111, and O157 and their effects on Shiga toxin releases.

Authors:  John Hwa Lee; Barry D Stein
Journal:  J Microbiol Biotechnol       Date:  2009-10       Impact factor: 2.351

4.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

5.  The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients.

Authors:  S Dundas; W T Todd; A I Stewart; P S Murdoch; A K Chaudhuri; S J Hutchinson
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

6.  Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.

Authors:  X Zhang; A D McDaniel; L E Wolf; G T Keusch; M K Waldor; D W Acheson
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

7.  German outbreak of Escherichia coli O104:H4 associated with sprouts.

Authors:  Udo Buchholz; Helen Bernard; Dirk Werber; Merle M Böhmer; Cornelius Remschmidt; Hendrik Wilking; Yvonne Deleré; Matthias an der Heiden; Cornelia Adlhoch; Johannes Dreesman; Joachim Ehlers; Steen Ethelberg; Mirko Faber; Christina Frank; Gerd Fricke; Matthias Greiner; Michael Höhle; Sofie Ivarsson; Uwe Jark; Markus Kirchner; Judith Koch; Gérard Krause; Petra Luber; Bettina Rosner; Klaus Stark; Michael Kühne
Journal:  N Engl J Med       Date:  2011-10-26       Impact factor: 91.245

8.  Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota.

Authors:  Kirk E Smith; Peter R Wilker; Paul L Reiter; Erin B Hedican; Jeff B Bender; Craig W Hedberg
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

9.  Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response.

Authors:  P T Kimmitt; C R Harwood; M R Barer
Journal:  Emerg Infect Dis       Date:  2000 Sep-Oct       Impact factor: 6.883

10.  Analysis of collection of hemolytic uremic syndrome-associated enterohemorrhagic Escherichia coli.

Authors:  Alexander Mellmann; Martina Bielaszewska; Robin Köck; Alexander W Friedrich; Angelika Fruth; Barbara Middendorf; Dag Harmsen; M Alexander Schmidt; Helge Karch
Journal:  Emerg Infect Dis       Date:  2008-08       Impact factor: 6.883

View more
  79 in total

1.  The SOS Response Mediates Sustained Colonization of the Mammalian Gut.

Authors:  Amanda N Samuels; Manuela Roggiani; Jun Zhu; Mark Goulian; Rahul M Kohli
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Therapy: Azithromycin and decolonization after HUS.

Authors:  Michael E Seifert; Phillip I Tarr
Journal:  Nat Rev Nephrol       Date:  2012-05-01       Impact factor: 28.314

3.  Plasmid-Mediated Quinolone Resistance in Different Diarrheagenic Escherichia coli Pathotypes Responsible for Complicated, Noncomplicated, and Traveler's Diarrhea Cases.

Authors:  Silvia Herrera-León; María Teresa Llorente; Sergio Sánchez
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

4.  A Putative Microcin Amplifies Shiga Toxin 2a Production of Escherichia coli O157:H7.

Authors:  Hillary M Mosso; Lingzi Xiaoli; Kakolie Banerjee; Maria Hoffmann; Kuan Yao; Edward G Dudley
Journal:  J Bacteriol       Date:  2019-12-06       Impact factor: 3.490

Review 5.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Authors:  Stephen B Freedman; Jianling Xie; Madisen S Neufeld; William L Hamilton; Lisa Hartling; Phillip I Tarr; Alberto Nettel-Aguirre; Anderson Chuck; Bonita Lee; David Johnson; Gillian Currie; James Talbot; Jason Jiang; Jim Dickinson; Jim Kellner; Judy MacDonald; Larry Svenson; Linda Chui; Marie Louie; Martin Lavoie; Mohamed Eltorki; Otto Vanderkooi; Raymond Tellier; Samina Ali; Steven Drews; Tim Graham; Xiao-Li Pang
Journal:  Clin Infect Dis       Date:  2016-02-24       Impact factor: 9.079

Review 6.  Taming the Beast: Interplay between Gut Small Molecules and Enteric Pathogens.

Authors:  Aman Kumar; Melissa Ellermann; Vanessa Sperandio
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

7.  Antibiotic-Mediated Modulations of Outer Membrane Vesicles in Enterohemorrhagic Escherichia coli O104:H4 and O157:H7.

Authors:  Andreas Bauwens; Lisa Kunsmann; Helge Karch; Alexander Mellmann; Martina Bielaszewska
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 8.  Dissecting the effects of antibiotics on horizontal gene transfer: Analysis suggests a critical role of selection dynamics.

Authors:  Allison J Lopatkin; Tatyana A Sysoeva; Lingchong You
Journal:  Bioessays       Date:  2016-10-04       Impact factor: 4.345

Review 9.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

10.  Polysorbates prevent biofilm formation and pathogenesis of Escherichia coli O104:H4.

Authors:  Rudolph E Sloup; Roberto J Cieza; David B Needle; Robert B Abramovitch; Alfredo G Torres; Christopher M Waters
Journal:  Biofouling       Date:  2016-10       Impact factor: 3.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.